Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RSVpreF

Vaccine (Recombinant protein vaccine) · Immune activation · developed by Pfizer

Phase 3 Most advanced trial
PFE Developer
1 Registered trials

What is RSVpreF?

RSVpreF is a vaccine directed at the prefusion F protein of respiratory syncytial virus, intended to induce immune responses against the virus. It is being studied for the prevention of respiratory syncytial virus (RSV) disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Recombinant protein vaccine)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07839871 Phase 3 Respiratory Syncytial Virus (RSV) Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Respiratory Syncytial Virus (RSV)

More from Pfizer

Follow PFE, the company behind RSVpreF

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.